Sana Biotechnology and Mayo Clinic Team Up for Potential Type 1 Diabetes Cure
The two have partnered to develop SC451, an investigational cell therapy aiming to restore the body’s ability to regulate glucose and eliminate the need for both insulin and immunosuppressive therapy.
An Islet Cell Transplant Without Immunosuppression Shows Promise - We Spoke with Patient #1
Encapsulated neonatal pig islet cells, implanted without immunosuppression in the OPF-310 trial, cut a type 1 diabetes patient’s insulin needs in half at six months, with further maturation expected.
